@prefix this: . @prefix sub: . @prefix prov: . @prefix dct: . @prefix pav: . @prefix orcid: . @prefix codebase: . @prefix version: . @prefix instance: . @prefix process: . @prefix np: . @prefix rdfs: . @prefix xsd: . @prefix v: . @prefix d: . @prefix dv: . @prefix dr: . @prefix dcat: . @prefix npx: . sub:head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:publicationInfo; a np:Nanopublication . } sub:assertion { d:DB00038 v:identifier "DB00038"; v:namespace "drugbank"; v:uri "http://bio2rdf.org/drugbank:DB00038"; v:x-identifiers.org ; dv:drugbank-id "BIOD00021", "BTD00021", "DB00038"; dv:x-atc ; dv:x-cas ; dv:x-genbank ; dv:x-ndc ; dv:x-pharmgkb ; dv:x-uniprot ; dv:x-wikipedia ; dct:description """Oprelvekin, the active ingredient in Neumega® is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo. The primary hematopoietic activity of Neumega® is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega® has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega® improved platelet nadirs and accelerated platelet recoveries compared to controls. In animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines."""@en; dct:identifier "drugbank:DB00038"; dct:title "Oprelvekin"@en; a dv:Drug; rdfs:label "Oprelvekin [drugbank:DB00038]"@en; rdfs:seeAlso , , . } sub:provenance { sub:assertion prov:wasDerivedFrom . dr:bio2rdf.dataset.drugbank.R3 dcat:distribution . dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime; prov:wasDerivedFrom . pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime; prov:wasDerivedFrom . prov:wasAttributedTo . } sub:publicationInfo { sub:signature.MCwCFA7VCAP3lA8S npx:hasPublicKey "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"; npx:hasSignature "MCwCFA7VCAP3lA8SdYcJWjoHZxvD3crUAhQ+LNlru+d7LvoZNr35mGpOGCwSgQ=="; npx:signedBy instance: . this: dct:created "2018-03-30T11:10:56.597+02:00"^^xsd:dateTime; dct:license ; npx:hasSignatureElement sub:signature.MCwCFA7VCAP3lA8S; prov:wasGeneratedBy process: . instance: prov:specializationOf codebase:; prov:wasAttributedTo orcid:0000-0002-1267-0234 . process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475"; prov:used version:; prov:wasAssociatedWith instance:; prov:wasStartedBy orcid:0000-0002-1267-0234 . version: dct:isVersionOf codebase:; pav:version "eda7951a5f6c622c5d2132f50c3093138484a349"; prov:wasAttributedTo orcid:0000-0002-1267-0234 . }